{"id":620562,"date":"2022-10-11T16:58:01","date_gmt":"2022-10-11T16:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=620562"},"modified":"2022-10-11T16:58:01","modified_gmt":"2022-10-11T16:58:01","slug":"heart-failure-pipeline-clinical-trials-approcals-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-bayer-amgen-juventas-therapeutics-glaxosmithkline-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/heart-failure-pipeline-clinical-trials-approcals-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-bayer-amgen-juventas-therapeutics-glaxosmithkline-and-many-others_620562.html","title":{"rendered":"Heart failure Pipeline: Clinical trials, Approcals, Emerging Therapies and Key pharma players involved by DelveInsight | Bayer, Amgen, Juventas Therapeutics, GlaxoSmithKline and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1665481298.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Heart failure Pipeline: Clinical trials, Approcals, Emerging Therapies and Key pharma players involved by DelveInsight | Bayer, Amgen, Juventas Therapeutics, GlaxoSmithKline and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1665481298.jpeg\" alt=\"Heart failure Pipeline: Clinical trials, Approcals, Emerging Therapies and Key pharma players involved by DelveInsight | Bayer, Amgen, Juventas Therapeutics, GlaxoSmithKline and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Heart failure Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Heart failure<\/strong>, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are disrupted. Certain conditions, such as narrowed arteries in the heart (coronary artery disease) or high blood pressure, gradually leave the heart too weak or stiff to fill and pump efficiently. Heart failure can be diagnosed based on the medical and family history, a physical exam, and test results. Treating heart failure depends on the severity of the condition. Diagnostic tests include: electrocardiogram, chest X-Ray, echocardiography etc. Treatments usually include heart-healthy lifestyle changes, medicines, and ongoing care.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Heart failure Pipeline Insight, 2022<\/strong>&rdquo; report provides comprehensive insights about <strong>100+ companies and 100+ pipeline drugs<\/strong> in Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/c75e1a1a5eaf4ad728c1bb0fd752ecd1.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Know more about Heart failure Report, click here: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Heart failure Pipeline Insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the <\/strong><strong>Heart failure<\/strong><strong> companies<\/strong><strong> working in the market are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Eli Lilly and Company<\/li>\n<li>Bayer<\/li>\n<li>BioCardia<\/li>\n<li>Mesoblast Inc.<\/li>\n<li>Janssen Research &amp; Development<\/li>\n<li>&nbsp;Pfizer<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Actelion Pharmaceuticals<\/li>\n<li>Tasly Pharmaceuticals<\/li>\n<li>Ionis Pharmaceuticals<\/li>\n<li>Innolife<\/li>\n<li>Imara Inc<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Stealth BioTherapeutics<\/li>\n<li>Bristol Myers Squibb<\/li>\n<li>Berlin Cures<\/li>\n<li>Bayer<\/li>\n<li>AstraZeneca<\/li>\n<li>Regeneron Pharmaceuticals<\/li>\n<li>GlaxoSmithKline<\/li>\n<li>SQ Innovation<\/li>\n<li>Recardio<\/li>\n<li>BIAL<\/li>\n<li>AstraZeneca<\/li>\n<li>Bristol Myers Squibb<\/li>\n<li>Imbria Pharmaceuticals<\/li>\n<li>Tenaya Therapeutics<\/li>\n<li>RibomicAnd Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Heart failure report covers around 100+ products under different phases of clinical development like:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage Heart failure products (Phase III)<\/li>\n<li>Mid-stage Heart failure products (Phase II and Phase I\/II)<\/li>\n<li>Early-stage Heart failure products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Heart failure Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Heart failure Pipeline sample report to know in detail about the Heart failure product segmentation: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Phases of Heart failure Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of Heart failure Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Finerenone (BAY94-8862)<\/li>\n<li>Omecamtiv Mecarbil<\/li>\n<li>ACRX-100<\/li>\n<li>GSK2798745<\/li>\n<li>LMI 1195-101<\/li>\n<li>Elamipretide<\/li>\n<li>FA relaxin<\/li>\n<li>BMS-986231<\/li>\n<li>Rexlemestrocel-L<\/li>\n<li>CardiAMP Cell Therapy<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Click here to know more about the Heart failure therapeutic assessment @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Heart failure treatment drugs and therapies<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Current Heart failure Treatment Scenario and Heart failure Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Heart failure drugs?<\/li>\n<li>How many Heart failure drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Heart failure therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Heart failure and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Click here to know more about the recent developments in the heart failure domain @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Advancements in Heart failure Clinical trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Heart Failure: Overview<\/p>\n<p style=\"text-align: justify;\">Causes<\/p>\n<p style=\"text-align: justify;\">Mechanism of Action<\/p>\n<p style=\"text-align: justify;\">Signs and Symptoms<\/p>\n<p style=\"text-align: justify;\">Diagnosis<\/p>\n<p style=\"text-align: justify;\">Treatment<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\">Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\">Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\">Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\">Heart Failure &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Tirzepatide: Eli Lilly and Company<\/p>\n<p style=\"text-align: justify;\">Product Description<\/p>\n<p style=\"text-align: justify;\">Research and Development<\/p>\n<p style=\"text-align: justify;\">Product Development Activities<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">AZD-8601: AstraZeneca<\/p>\n<p style=\"text-align: justify;\">Product Description<\/p>\n<p style=\"text-align: justify;\">Research and Development<\/p>\n<p style=\"text-align: justify;\">Product Development Activities<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Drug name: Company name<\/p>\n<p style=\"text-align: justify;\">Product Description<\/p>\n<p style=\"text-align: justify;\">Research and Development<\/p>\n<p style=\"text-align: justify;\">Product Development Activities<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">AZD-3427: AstraZeneca<\/p>\n<p style=\"text-align: justify;\">Product Description<\/p>\n<p style=\"text-align: justify;\">Research and Development<\/p>\n<p style=\"text-align: justify;\">Product Development Activities<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">RBM-003: Ribomic<\/p>\n<p style=\"text-align: justify;\">Product Description<\/p>\n<p style=\"text-align: justify;\">Research and Development<\/p>\n<p style=\"text-align: justify;\">Product Development Activities<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Heart Failure Key Companies<\/p>\n<p style=\"text-align: justify;\">Heart Failure Key Products<\/p>\n<p style=\"text-align: justify;\">Heart Failure &#8211; Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Heart Failure &#8211; Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Heart Failure &#8211; Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Heart Failure Analyst Views<\/p>\n<p style=\"text-align: justify;\">Heart Failure Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/heart-failure-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/heart-failure-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=heart-failure-pipeline-clinical-trials-approcals-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-bayer-amgen-juventas-therapeutics-glaxosmithkline-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=heart-failure-pipeline-clinical-trials-approcals-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-bayer-amgen-juventas-therapeutics-glaxosmithkline-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Heart failure Pipeline Heart failure, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/heart-failure-pipeline-clinical-trials-approcals-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-bayer-amgen-juventas-therapeutics-glaxosmithkline-and-many-others_620562.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,404],"tags":[],"class_list":["post-620562","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/620562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=620562"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/620562\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=620562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=620562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=620562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}